vs
Side-by-side financial comparison of Cue Biopharma, Inc. (CUE) and Zeo Energy Corp. (ZEO). Click either name above to swap in a different company.
Cue Biopharma, Inc. is the larger business by last-quarter revenue ($21.9M vs $18.6M, roughly 1.2× Zeo Energy Corp.). Cue Biopharma, Inc. runs the higher net margin — 7.2% vs -10.8%, a 18.0% gap on every dollar of revenue. On growth, Cue Biopharma, Inc. posted the faster year-over-year revenue change (1292.3% vs -0.4%). Over the past eight quarters, Cue Biopharma, Inc.'s revenue compounded faster (257.5% CAGR vs -4.0%).
Cue Biopharma is a clinical-stage biotechnology company focused on developing novel targeted immunotherapies for cancer, autoimmune disorders, and inflammatory diseases. Its proprietary platform enables precise T-cell activity modulation, with core operations in North America and global pharma partnerships to advance lead product candidates through clinical trials.
CUE vs ZEO — Head-to-Head
Income Statement — Q4 FY2025 vs Q4 FY2025
| Metric | | |
|---|---|---|
| Revenue | $21.9M | $18.6M |
| Net Profit | $1.6M | $-2.0M |
| Gross Margin | — | — |
| Operating Margin | 9.0% | -11.8% |
| Net Margin | 7.2% | -10.8% |
| Revenue YoY | 1292.3% | -0.4% |
| Net Profit YoY | 116.7% | -360.9% |
| EPS (diluted) | $0.05 | — |
Green = leading value per metric. Periods may differ when fiscal calendars don't align.
8-Quarter Revenue & Profit Trend
Side-by-side quarterly history. Quarters aligned by calendar period so offset fiscal years line up.
| Q4 25 | $21.9M | $18.6M | ||
| Q3 25 | $2.1M | $23.9M | ||
| Q2 25 | $3.0M | $18.1M | ||
| Q1 25 | $421.0K | $8.8M | ||
| Q4 24 | $1.6M | $18.6M | ||
| Q3 24 | $3.3M | $19.7M | ||
| Q2 24 | $2.7M | $14.8M | ||
| Q1 24 | $1.7M | $20.1M |
| Q4 25 | $1.6M | $-2.0M | ||
| Q3 25 | $-7.4M | $-3.2M | ||
| Q2 25 | $-8.5M | $-2.4M | ||
| Q1 25 | $-12.3M | $-6.4M | ||
| Q4 24 | — | $-435.3K | ||
| Q3 24 | $-8.7M | $-424.3K | ||
| Q2 24 | $-10.2M | $-277.8K | ||
| Q1 24 | $-12.3M | $-1.5M |
| Q4 25 | — | — | ||
| Q3 25 | — | 57.9% | ||
| Q2 25 | — | 59.8% | ||
| Q1 25 | — | 99.3% | ||
| Q4 24 | — | — | ||
| Q3 24 | — | 50.2% | ||
| Q2 24 | — | 52.3% | ||
| Q1 24 | — | — |
| Q4 25 | 9.0% | -11.8% | ||
| Q3 25 | -353.4% | -8.3% | ||
| Q2 25 | -292.3% | -15.8% | ||
| Q1 25 | -2921.4% | -153.8% | ||
| Q4 24 | — | -6.0% | ||
| Q3 24 | -264.2% | -15.2% | ||
| Q2 24 | -390.6% | -18.0% | ||
| Q1 24 | -737.8% | -20.1% |
| Q4 25 | 7.2% | -10.8% | ||
| Q3 25 | -346.6% | -13.5% | ||
| Q2 25 | -287.1% | -13.3% | ||
| Q1 25 | -2911.4% | -72.4% | ||
| Q4 24 | — | -2.3% | ||
| Q3 24 | -259.6% | -2.2% | ||
| Q2 24 | -382.7% | -1.9% | ||
| Q1 24 | -719.1% | -7.6% |
| Q4 25 | $0.05 | — | ||
| Q3 25 | $-0.07 | — | ||
| Q2 25 | $-0.09 | — | ||
| Q1 25 | $-0.17 | $-0.48 | ||
| Q4 24 | — | $1.11 | ||
| Q3 24 | $-0.17 | $-0.08 | ||
| Q2 24 | $-0.20 | $0.03 | ||
| Q1 24 | $-0.25 | $-1.54 |
Balance Sheet & Financial Strength
Snapshot of each company's liquidity, leverage and book value from the latest quarter.
| Metric | | |
|---|---|---|
| Cash + ST InvestmentsLiquidity on hand | $27.1M | $6.1M |
| Total DebtLower is stronger | — | $79.1K |
| Stockholders' EquityBook value | $26.4M | $5.3M |
| Total Assets | $42.2M | $56.9M |
| Debt / EquityLower = less leverage | — | 0.01× |
8-quarter trend — quarters aligned by calendar period.
| Q4 25 | $27.1M | $6.1M | ||
| Q3 25 | $11.7M | $3.9M | ||
| Q2 25 | $27.5M | $68.7K | ||
| Q1 25 | $13.1M | $2.9M | ||
| Q4 24 | $22.5M | $5.6M | ||
| Q3 24 | $32.4M | $4.3M | ||
| Q2 24 | $30.0M | $5.3M | ||
| Q1 24 | $41.0M | — |
| Q4 25 | — | $79.1K | ||
| Q3 25 | — | $84.6K | ||
| Q2 25 | — | $642.8K | ||
| Q1 25 | — | $715.4K | ||
| Q4 24 | — | $787.7K | ||
| Q3 24 | $1.0M | $858.6K | ||
| Q2 24 | $2.0M | $1.6M | ||
| Q1 24 | $3.0M | $748.8K |
| Q4 25 | $26.4M | $5.3M | ||
| Q3 25 | $13.2M | $-1.7M | ||
| Q2 25 | $18.2M | $-59.4M | ||
| Q1 25 | $6.6M | $-23.1M | ||
| Q4 24 | $17.5M | $-88.9M | ||
| Q3 24 | $25.4M | $-39.3M | ||
| Q2 24 | $21.6M | $-53.0M | ||
| Q1 24 | $30.0M | $-173.0M |
| Q4 25 | $42.2M | $56.9M | ||
| Q3 25 | $31.6M | $58.5M | ||
| Q2 25 | $40.7M | $46.2M | ||
| Q1 25 | $22.3M | $47.4M | ||
| Q4 24 | $32.2M | $61.0M | ||
| Q3 24 | $44.8M | $47.1M | ||
| Q2 24 | $42.3M | $49.1M | ||
| Q1 24 | $54.0M | $50.1M |
| Q4 25 | — | 0.01× | ||
| Q3 25 | — | — | ||
| Q2 25 | — | — | ||
| Q1 25 | — | — | ||
| Q4 24 | — | — | ||
| Q3 24 | 0.04× | — | ||
| Q2 24 | 0.09× | — | ||
| Q1 24 | 0.10× | — |
Cash Flow & Capital Efficiency
How much cash each business actually produces after reinvestment. Cash flow is harder to manipulate than net income.
| Metric | | |
|---|---|---|
| Operating Cash FlowLast quarter | $-1.1M | $2.4M |
| Free Cash FlowOCF − Capex | — | $2.3M |
| FCF MarginFCF / Revenue | — | 12.2% |
| Capex IntensityCapex / Revenue | 0.0% | 0.9% |
| Cash ConversionOCF / Net Profit | -0.68× | — |
| TTM Free Cash FlowTrailing 4 quarters | — | $-9.9M |
8-quarter trend — quarters aligned by calendar period.
| Q4 25 | $-1.1M | $2.4M | ||
| Q3 25 | $-9.0M | $-6.6M | ||
| Q2 25 | $-3.4M | $-2.3M | ||
| Q1 25 | $-8.2M | $-2.3M | ||
| Q4 24 | $-36.3M | $3.5M | ||
| Q3 24 | $-7.5M | $162.2K | ||
| Q2 24 | $-10.0M | $-2.2M | ||
| Q1 24 | $-9.8M | $-10.2M |
| Q4 25 | — | $2.3M | ||
| Q3 25 | — | $-6.8M | ||
| Q2 25 | $-3.4M | $-2.7M | ||
| Q1 25 | $-8.3M | $-2.6M | ||
| Q4 24 | $-36.4M | $3.4M | ||
| Q3 24 | $-7.5M | $116.5K | ||
| Q2 24 | $-10.0M | $-2.3M | ||
| Q1 24 | $-9.8M | $-10.4M |
| Q4 25 | — | 12.2% | ||
| Q3 25 | — | -28.6% | ||
| Q2 25 | -116.5% | -15.0% | ||
| Q1 25 | -1976.7% | -30.0% | ||
| Q4 24 | -2309.3% | 18.2% | ||
| Q3 24 | -225.7% | 0.6% | ||
| Q2 24 | -376.2% | -15.6% | ||
| Q1 24 | -573.0% | -51.5% |
| Q4 25 | 0.0% | 0.9% | ||
| Q3 25 | 0.0% | 1.0% | ||
| Q2 25 | 0.9% | 2.4% | ||
| Q1 25 | 35.6% | 4.2% | ||
| Q4 24 | 4.2% | 0.5% | ||
| Q3 24 | 0.0% | 0.2% | ||
| Q2 24 | 0.4% | 0.7% | ||
| Q1 24 | 3.2% | 1.1% |
| Q4 25 | -0.68× | — | ||
| Q3 25 | — | — | ||
| Q2 25 | — | — | ||
| Q1 25 | — | — | ||
| Q4 24 | — | — | ||
| Q3 24 | — | — | ||
| Q2 24 | — | — | ||
| Q1 24 | — | — |
Financial Flow Comparison
Revenue → gross profit → operating profit → net profit for each company.
Revenue Breakdown by Segment
CUE
| Immuno Scape Collaboration And License Agreement | $9.5M | 43% |
| BI Collaboration And License Agreement | $8.1M | 37% |
| Other | $4.3M | 20% |
ZEO
| Nonrelated Party | $18.1M | 98% |
| Related Party | $432.1K | 2% |
